Case-Based Learning: Progressive Proteinuria With Preserved Kidney Function

Abstract

Proteinuria is a well-established marker of kidney damage and a significant predictor of renal and cardiovascular outcomes. However, a subset of patients exhibit progressive proteinuria despite preserved glomerular filtration rate (GFR), presenting diagnostic and management challenges. This review examines the latest evidence regarding the mechanisms, clinical implications, and optimal management strategies for progressive proteinuria in the context of maintained kidney function, integrating recent guideline recommendations and emerging therapies relevant to clinical practice.

Introduction

The presence of proteinuria, defined by elevated urinary protein excretion, is often associated with chronic kidney disease (CKD) and declining renal function. Nonetheless, progressive proteinuria can occur independently of GFR reduction, raising important considerations for nephrologists and other healthcare professionals. Recognizing and addressing this clinical scenario is critical, as persistent proteinuria is independently linked to adverse renal and cardiovascular outcomes, even when kidney function is preserved. This article explores the multifaceted aspects of progressive proteinuria with preserved GFR, providing a comprehensive review for clinicians.

Epidemiology / Disease Burden

Proteinuria affects an estimated 8-10% of the adult population, with prevalence rates rising in populations with diabetes, hypertension, and aging. Among these, a noteworthy proportion exhibit significant albuminuria or non-selective proteinuria while maintaining eGFR >60 mL/min/1.73m². Epidemiological data from large cohorts, such as NHANES and CKD Prognosis Consortium studies, indicate that individuals with isolated proteinuria are at increased risk for progression to overt CKD, cardiovascular events, and mortality, underscoring the public health significance of this phenotype. In clinical practice, detecting progressive proteinuria in patients with stable GFR is becoming increasingly common due to routine screening and improved sensitivity of urinary assays.

Pathophysiology

The mechanisms underlying progressive proteinuria with preserved kidney function are complex and multifactorial. Glomerular hyperfiltration, podocyte injury, and altered glomerular basement membrane permeability are central to excessive protein leakage. Early diabetic nephropathy, primary glomerulopathies (such as minimal change disease or early membranous nephropathy), and genetic disorders affecting podocyte structure can manifest as progressive proteinuria without immediate reduction in GFR. Additionally, systemic inflammation, endothelial dysfunction, and alterations in tubular protein handling contribute to the pathogenesis. Notably, persistent proteinuria itself can perpetuate renal injury by inducing tubular interstitial inflammation and fibrosis, creating a vicious cycle that ultimately threatens renal function.

Risk Factors

Several risk factors predispose individuals to progressive proteinuria while maintaining kidney function. Diabetes mellitus, particularly in the early stages, is a leading cause due to glomerular hyperfiltration and increased intraglomerular pressure. Hypertension, even when well-controlled, can independently promote glomerular injury. Other risk factors include obesity, metabolic syndrome, family history of kidney disease, certain ethnic backgrounds (e.g., African descent), and exposure to nephrotoxic agents such as nonsteroidal anti-inflammatory drugs (NSAIDs) or certain antibiotics. Genetic variants affecting podocyte proteins (e.g., NPHS2, ACTN4) are increasingly recognized in younger patients or those with familial clustering.

Clinical Features

Patients with progressive proteinuria and preserved kidney function are frequently asymptomatic, highlighting the importance of routine urine screening in at-risk populations. When present, clinical features may include foamy urine, subtle edema, or findings related to the underlying etiology (e.g., rash in systemic lupus erythematosus). Laboratory evaluation typically reveals isolated proteinuria predominantly albuminuria or non-selective proteinuria without hematuria or casts. Blood pressure may be elevated, and metabolic parameters are often abnormal in those with metabolic syndrome or diabetes. Serial monitoring is essential to assess proteinuria progression and to exclude confounding factors such as urinary tract infection or orthostatic proteinuria in younger patients.

Diagnosis

Diagnosis begins with quantification of proteinuria using spot urine protein-to-creatinine or albumin-to-creatinine ratios, with confirmation by 24-hour urine collection if needed. A thorough history and physical examination aid in identifying secondary causes. Laboratory workup includes renal function tests, serum albumin, lipid profile, and serologic studies for autoimmune or infectious etiologies. Renal ultrasound is performed to exclude structural abnormalities. In cases of unexplained or significant proteinuria (>1 g/day) with preserved GFR, a kidney biopsy may be indicated to determine the underlying pathology and guide management. Early diagnosis is crucial for prognostication and intervention.

Treatment & Management

The cornerstone of management is addressing the underlying cause and mitigating risk factors. Renin-angiotensin-aldosterone system (RAAS) blockade, via angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), remains first-line therapy to reduce proteinuria and protect renal and cardiovascular health. Optimization of glycemic and blood pressure control is paramount in diabetic and hypertensive patients. Lifestyle modifications, including dietary sodium restriction, weight loss, and smoking cessation, are universally recommended. For patients with primary glomerular diseases, immunosuppressive therapy may be indicated based on biopsy findings and risk stratification. Regular monitoring of proteinuria and renal function guides therapy adjustment. Multidisciplinary care involving nephrologists, primary care, and other specialists enhances long-term outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in the management of proteinuria, particularly with the advent of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Large randomized trials, such as DAPA-CKD and EMPA-KIDNEY, demonstrated that SGLT2 inhibitors reduce proteinuria and slow CKD progression, even in patients with preserved GFR. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has shown promise in reducing albuminuria and improving cardiovascular outcomes in diabetic kidney disease. Research into endothelin receptor antagonists, podocyte-targeted therapies, and novel anti-inflammatory agents is ongoing and may offer additional options for patients with refractory proteinuria. Genetic testing and personalized medicine approaches are increasingly utilized in selected populations.

Guideline Recommendations

Major nephrology guidelines, including those from KDIGO and the American Diabetes Association, emphasize early detection and intervention for proteinuria, regardless of GFR. Universal annual screening is advised for high-risk groups such as diabetics and hypertensives. Initiation and titration of RAAS inhibitors are recommended for persistent proteinuria >30 mg/g, with SGLT2 inhibitors now endorsed for appropriate patients. Regular monitoring and risk factor modification remain foundational. For patients with unexplained or rapidly progressive proteinuria, timely referral to nephrology and consideration of kidney biopsy are advised. Guidelines also stress the importance of patient education and adherence to therapy.

Conclusion

Progressive proteinuria with preserved kidney function represents a clinically significant entity that warrants vigilant assessment and proactive management. Early recognition, accurate diagnosis, and evidence-based intervention are essential to reduce the risk of future renal and cardiovascular complications. Recent therapeutic advances offer new hope for improving outcomes, but individualized care and adherence to guideline recommendations remain paramount. Ongoing research will continue to refine our understanding and approach to this challenging clinical scenario, further optimizing patient care and prognosis.